Celldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on Monday

Celldex Therapeutics (NASDAQ:CLDX) will likely be announcing its earnings results before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $1.31 million for the quarter.

Celldex Therapeutics Trading Down 0.6 %

Celldex Therapeutics stock opened at $22.46 on Friday. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.74 and a beta of 1.60. Celldex Therapeutics has a 1-year low of $20.91 and a 1-year high of $53.18. The firm has a 50 day simple moving average of $24.33 and a 200 day simple moving average of $29.37.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CLDX shares. UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $60.22.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.